Navigation Links
ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
Date:8/23/2007

Protocols on ImmuneRegen's Homspera(TM) Submitted to RFI, 'Therapeutic

Countermeasures against CDC Category A and B Threat Agents'

SCOTTSDALE, Ariz., Aug. 23 /PRNewswire-FirstCall/ -- Research and development biotechnology company ImmuneRegen BioSciences, Inc. a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO.OB), announced today that it has recently responded to a Request for Information (RFI) from the Defense Threat Reduction Agency (DTRA) of the Department of Defense for Therapeutic Countermeasures against CDC Category A and B Threat Agents. ImmuneRegen made its submission August 20, 2007 with information on its potential treatment, Homspera(TM).

ImmuneRegen filed a formal response to the RFI respective to its compound Homspera(TM), currently in development as a therapeutic and prophylactic countermeasure against multiple pathogens including multiple biological, chemical and radiological threats. For the purposes of this request, the RFI submission focuses primarily on anthrax countermeasures.

"We believe that Homspera is at the forefront of the development of Category A and B countermeasures," commented Michael Wilhelm, co-founder and CEO of ImmuneRegen. "Our studies have shown Homspera to be effective in protecting experimental animals against the lethal effects of ionizing radiation, infection with anthrax spores, infection with influenza virus, and to be an adjuvant in influenza vaccine studies. We believe Homspera's mode of action includes an immunostimulatory activity that results in enhanced host defenses against multiple pathogens."

Should this RFI lead to further studies, ImmuneRegen expects to partner with appropriate governmental agencies, such as USAMRIID (U.S. Army Medical Research Institute for Infectious Diseases) or AFIP (Armed Forces Institute of Pathology).

About Homspera(TM)

Homspera is a generic name used by the Company to describe the synthetic peptide Sar9, Met (O2)11-Substance P. Sar9, Met (O2)11-Substance P is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species. All of the Company's research and development efforts are early, pre-clinical stage and Homspera(TM), as Viprovex(R) and Radilex(TM), has only undergone exploratory studies to evaluate its biological activity in small animals.

About ImmuneRegen BioSciences, Inc.

IR BioSciences Holdings, Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera(R) and its derivatives Radilex(TM) and Viprovex(R), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system. For more information, please visit the company's website at http://www.immuneregen.com.

Statements about the Company's future expectations, including statements about the potential for the Company's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. The Company's actual results could differ materially from expected results as a result of a number of factors, including the fact that preliminary results involved only a small number of test mice, the subsequent investigations were limited in scope, the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs, (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials) the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in the Company's periodic report on Form 10-QSB for the three months ended June 30, 2007 and on Form 10-KSB for the twelve months ended December 31, 2006 as filed with the Securities and Exchange Commission. There are no guarantees that any of the Company's proposed products will prove to be commercially successful. The Company undertakes no duty to update forward-looking statements.

MEDIA CONTACT:

W. Jason Grimley

Spelling Communications

310-477-9500

jgrimley@spellcom.com


'/>"/>
SOURCE ImmuneRegen BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Third Wave responds to Digene patent lawsuit
2. Epic responds to critics of electronic record installation
3. Small Tree Communications awarded $2.85M defense contract
4. Research consortium aims to bring security and defense contracts to Wisconsin
5. MATC student team wins cyber defense contest
6. National Bio and Agro Defense fits Wisconsin
7. Chippewa Valley firms land more defense work
8. Wisconsins failure to attract federal defense dollars crimps tech economy
9. Defense contract helps Plexus gain record profits
10. Chippewa Valley to get $46 million in defense spending
11. Wisconsins untapped defense might: why saving military bases is just a start
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):